FTSE MIB
34.244,33 -26,79 (-0,08%) Dow Jones
38.460,92 -42,77 (-0,11%) Nasdaq
15.712,75 +16,11 (+0,10%) Nikkei 225
37.628,48 -831,60 (-2,16%) Petrolio
82,92 +0,11 (+0,13%) Bitcoin EUR
59.988,84 -2.429,04 (-3,89%)
Terumo Corp (TUO.MU)
| Chiusura precedente | 15,80 |
| Aperto | 16,00 |
| Denaro | 15,40 x 0 |
| Lettera | 15,70 x 0 |
| Min-Max giorno | 16,00 - 16,00 |
| Intervallo di 52 settimane | 12,10 - 18,10 |
| Volume | |
| Media Volume | 0 |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireOrchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update
U.S. Food and Drug Administration (“FDA”) granted Investigational Device Exemption (“IDE”) approval with conditions for Virtue SAB® coronary in-stent restenosis (“ISR”) U.S. pivotal study (in collaboration with Terumo Corporation (“Terumo”)); study expected to start before the end of 2023BackBeat CNT™ global pivotal study in hypertensive pacemaker patients (in collaboration with Medtronic) on track for initiation in the second half of 2023 NEW HOPE, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Orchest
- GlobeNewswire
Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis
Virtue® Sirolimus AngioInfusion Balloon (“SAB”) is the only non-coated angioplasty system providing protected delivery of extended release sirolimus under clinical investigation worldwideVirtue ISR-US pivotal study focused on coronary in-stent restenosis (“ISR”), a difficult-to-treat and serious complication of coronary stenting, currently expected to start before the end of 2023Strategic partnership with Terumo Corporation (“Terumo”) targets coronary ISR and multiple additional vascular indicat
